The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
Van Dyke, Daniel L.
Rassenti, Laura Z.
Heerema, Nyla A.
Cin, Paola Dal
Aquila, Marie Dell
Greaves, Andrew W.
Kipps, Thomas J.
Kay, Neil E.Note: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationVan Dyke, D. L., L. Werner, L. Z. Rassenti, D. Neuberg, E. Ghia, N. A. Heerema, P. D. Cin, et al. 2016. “The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.” British journal of haematology 173 (1): 105-113. doi:10.1111/bjh.13933. http://dx.doi.org/10.1111/bjh.13933.
AbstractSummary This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well-documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27822205
- HMS Scholarly Articles 
Contact administrator regarding this item (to report mistakes or request changes)